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Abstract
Background: Elevated heart rate is associated with increased cardiovascular morbidity. The selective If current inhibitor
ivabradine reduces heart rate without affecting cardiac contractility, and has been shown to be cardioprotective in the
failing heart. Ivabradine also exerts some of its beneficial effects by decreasing cardiac proinflammatory cytokines and
inhibiting peroxidants and collagen accumulation in atherosclerosis or congestive heart failure. However, the effects of
ivabradine in the setting of acute viral myocarditis and on the cytokines, oxidative stress and cardiomyocyte apoptosis have
not been investigated.
Methodology/Principal Findings: The study was designed to compare the effects of ivabradine and carvedilol in acute viral
myocarditis. In a coxsackievirus B3 murine myocarditis model (Balb/c), effects of ivabradine and carvedilol (a nonselective b-
adrenoceptor antagonist) on myocardial histopathological changes, cardiac function, plasma noradrenaline, cytokine levels,
cardiomyocyte apoptosis, malondialdehyde and superoxide dismutase contents were studied. Both ivabradine and
carvedilol similarly and significantly reduced heart rate, attenuated myocardial lesions and improved the impairment of left
ventricular function. In addition, ivabradine treatment as well as carvedilol treatment showed significant effects on altered
myocardial cytokines with a decrease in the amount of plasma noradrenaline. The increased myocardial MCP-1, IL-6, and
TNF-a. in the infected mice was significantly attenuated in the ivabradine treatment group. Only carvedilol had significant
anti-oxidative and anti-apoptoic effects in coxsackievirus B3-infected mice.
Conclusions/Significance: These results show that the protective effects of heart rate reduction with ivabradine and
carvedilol observed in the acute phase of coxsackievirus B3 murine myocarditis may be due not only to the heart rate
reduction itself but also to the downregulation of inflammatory cytokines.
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Introduction
Viral infection of the myocardium produces myocardial necrosis
and intense inflammation, which can cause acute heart failure in
human and animals [1,2]. Viral myocarditis is a common cause of
acute heart failure, especially in young patients [2]. In patients
with heart failure, heart rate (HR) has been shown to be directly
related to the risk of cardiac decompensation [3] and overall
mortality [4]. An elevated HR may impair ventricular diastolic
filling and increase myocardial oxygen demand. The beneficial
effects of HR reduction in this setting are well established [5,6]. b-
Blockade is the classical medication to achieve HR reduction, and
the main stay of modern therapy for heart failure. Less research
has been done for b-blockers in the area of viral myocarditis. We
and other investigators have recently reported that carvedilol, a
third-generation, nonselective b-adrenoceptor antagonist, reduced
myocardial inflammation and necrosis in murine viral myocarditis
[7–10]. The beneficial action of b-blockade in murine viral
myocarditis may be at least partly due to its HR-lowering effect.
However, b-blockade also has negative effects (e.g., negative
inotropism, and blood pressure reduction), which largely limits
their administration in the advent of acute heart failure. The
unwanted effects of b-blockers have stimulated the development of
drugs which more selectively reduce HR.
Ivabradine, a selective inhibitor of the I(f) channel, reduces
resting and exercise HRs without affecting cardiac contractility or
blood pressure [11]. Several experimental studies have demon-
strated that treatment with ivabradine improves global left
ventricular function and reduces cardiac collagen accumulation
in rats with congestive heart failure [12–14]. In the recent SHIFT
trial in patients with symptomatic heart failure and ejection
fraction below 35%, ivabradine reduced the primary composite
endpoint of cardiovascular death and hospital admission for
worsening of heart failure significantly [15]. In the SHIFT
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remodelling, with significant reductions in left ventricular volumes
and an increase in left ventricular ejection fraction (LVEF) in
patients with heart failure and left ventricular systolic dysfunction.
However, the mechanism for this improvement in left ventricular
volumes and function remains to be determined. Recent reports
have emphasized that this compound may have pleiotropic effects
beyond HR reduction [17,18]. Not all effects of ivabradine can be
reversed by atrial pacing [17,18]. Ivabradine also exerts some of its
beneficial effects by decreasing cardiac proinflammatory cytokines
and inhibiting peroxidants and collagen accumulation in athero-
sclerosis or congestive heart failure [19–22]. However, its effects in
acute experimental viral myocarditis are unknown. This study
therefore was designed to compare the effects of ivabradine and
carvedilol in a murine model of acute viral myocarditis induced by
coxsackievirus B3 (CVB3).
Methods
Murine Viral Myocarditis
Specific pathogen-free inbred, 4-week-old, male Balb/c mice,
obtained from Shanghai Laboratory Animal Center, China, were
inoculated intraperitoneally with 1.0610
6 plaque-forming units
(pfu) of CVB3 (strain Nancy) diluted in phosphate-buffered saline
to a final volume of 0.1 ml. Group control was inoculated
intraperitoneally 0.1 ml with normal saline solution. The day of
virus inoculation was defined as day 0. All experiments were
carried out in accordance with China Animal Welfare Legislation
and were approved by the Wenzhou Medical College Committee
on Ethics in the Care and Use of Laboratory Animals.
Drug Administration
Ivabradine and carvedilol were obtained from Servier Co.
(Courbevoie, France) and Roche China Co. (Shanghai, China),
respectively. Starting 24 h after infection ivabradine (10 mg/kg
per day, n=40) and carvedilol (10 mg/kg per day, n=40) were
administered by gavage for 14 consecutive days, whereas control
group (n=30) and myocarditis group (n=40) mice received the
normal saline solution in the same way. Eight surviving mice from
each group were killed on day 4, 7 or 14.
Hemodynamic Measurements
HR and blood pressure (BP) were measured using a photoelec-
tric tail cuff detection system (softron BP-98A from Japan) on
conscious mice that had been pre-warmed for 10 minutes at 37uC
in a thermostatically controlled heating cabinet. The values were
averaged from at least three consecutive readings on each
occasion.
Echocardiographic Examination
Transthoracic echocardiography was performed using a Sonos
5500 ultrasound machine (Phillips, USA.) with a 12 MHz phased
array transducer, real time digital acquisition, storage, and review
capabilities, as previously described [8]. The transducer was
covered with a surgical latex glove finger filled by ultrasound
transmission gel to provide a standoff of 0.5–0.7 cm. The
transducer was used at a depth setting of 2 cm to optimize
resolution. Mice were anaesthetized with intraperitoneally with
3% chloral hydrate (0.01 ml/g). The chest was shaved. Mice were
placed on a heating pad in a shallow left lateral position. Two-
dimensional, M-mode, Doppler flow images were obtained in
parasternal long-axis view. The left ventricular end-systolic and
end-diastolic internal diameters (LVESd, LVEDd) were measured
over the course of at least 3 consecutive cardiac cycles. The LVEF
and fractional shortening (FS) were then both calculated.
Plasma Noradrenaline
Plasma noradrenaline was measured using high-performance
liquid chromatography and electrochemical detection. After mice
were anesthetized intraperitoneally with pentobarbital (50 mg/kg),
the arterial blood samples were taken and centrifuged at 3000 g
for 15 min. The plasma were stored at 280uC for subsequent
determination of noradrenaline concentration.
Survival Rate
Survival was measured over a 14-day period.
Myocardial Histopathology
The ratio of heart weight to body weight (HW/BW) was
calculated. The heart tissue was fixed in 10% formalin, embedded
in paraffin, sectioned, and stained with hematoxylin and eosin.
Several sections of each heart were scored blindly by two
observers. The scores assigned to these specific sections were
Table 1. Primer sequences used for semi-quantitative RT-PCR.
mRNA Primers Annealing temperature (6C) Cycles Product (bp)
CVB3 F-CGGTACCTTTGTGCGCCTGT
R-CAGGCCGCCAACGCAGCC
61 30 314
MCP-1 F-GCCAACTCTCACTGAAGCC
R-GCTGGTGAATGAGTAGCAGC
50 30 161
IL-6 F-TGCTGGTGACAACCACGGCC
R-GTACTCCAGAAGACCAGAGG
60 33 308
TNF-a F-CCTGTAGCCCACGTCGTAGC
R-TTGACCTCAGCGCTGAGTTG
50 31 374
ICAM-1 F-CAACTGGAAGCTGTTTGAGCTG
R-TAGCTGGAAGATCGAAAGTCCG
59 33 437
VCAM-1 F-CCTCACTTGCAGCACTACGGGCT
R-TTTTCCAATATCCTCAATGACGGG
60 34 442
b-actin F-AGGGAAATCGTGCGTGACAT
R-CATCTGCTGGAAGGTGGACA
55 24 450
doi:10.1371/journal.pone.0039394.t001
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necrosis was graded and scored as follows: 0= no lesion; 1+ =
lesions involving ,25% of the myocardium; 2+ = lesions
involving 25% to 50%; 3+ = lesions involving 50 to 75%; and
4+ = lesions involving 75% to 100%.
RNA Isolation and Reverse Transcriptase-polymerase
Chain Reaction (RT-PCR)
Total RNA, frozen in liquid nitrogen, was extracted from the
myocardial samples by the Trizol method (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions. cDNA
was synthesized by reverse transcription using total RNA (3 mg) as
a template. Semiquantitative RT-PCR was used to detect the
mRNA abundance of monocyte chemoattractant protein-1 (MCP-
1), interleukin (IL)-6, tumor necrosis factor (TNF)-a, intercellular
adhesion molecule-1 (ICAM-1) and vascular cell adhesion
molecule-1 (VCAM-1) (Table 1). Additionally, RT-PCR was also
used to detect the CVB3 RNA abundance in the infected
myocardium. The mRNA abundance was quantified as optical
densities (OD) equalized with b-actin mRNA levels using a
BandScan 5.0 software (Glyko, Novato, CA, USA). Nucleicacid
sequences of all PCR products were confirmed to be identical to
published GenBank data.
Assay of Cytokine Levels in the Heart
Cytokine levels were measured with various enzyme-linked
immunosorbent assay (ELISA) kits manufactured by Westang
Biotech Co Ltd (Shanghai,China) for MCP-1, IL-6 and TNF-a.
The sensitivity of the kit is 8 pg/ml for MCP-1, 16 pg/ml for IL-6,
and 13 pg/ml for TNF-a. Cytokine levels are expressed as pg/mg
of heart.
Detection of Malondialdehyde (MDA) and Superoxide
Dismutase (SOD) Contents in Cardiac Homogenates
The myocardium was homogenized in 9 (v/v) volumes of ice-
cold PBS, and the homogenates were centrifuged at 30006g for
15 min at 4uC to obtain the supernate. MDA and SOD in cardiac
homogenates were measured by assay kits, respectively, according
to the manufacturer’s instructions. The kits were manufactured by
Jiancheng Co. (Nanjing, China).
Detection of Apoptosis
Apoptosis was detected in myocardial tissue sections using the
terminal transferase-mediated DNA nick end labelling (TUNEL)
assay. Apoptotic cells were identified using an in situ cell death
detection kit, pod (Roche, Switzerland). The myocardial tissue
sections were incubated with 50 ml TUNEL reaction mixture
containing terminal deoxynucleotidyl transferase (TdT) for 60
minutes at 37uC. After incubating with horseradish peroxidase
(HRP)-avidin (0.5 mg/ml in phosphate buffered saline) at 37uC for
30 minutes, they were stained with DAB and observed in 10
randomly selected fields by microscope. Nuclei with brown
staining indicated TUNEL positive cells. Cell death was expressed
as a percentage of total cells counted.
Statistical Analysis
All values were expressed as mean value 6 standard error (SE).
Survival rate was analyzed by the Kaplan-Meier method.
Statistical analysis was performed by one way analysis of variance
(ANOVA), followed by Fisher protected least significant difference
test. A value of P,0.05 was considered significant.
Figure 1. Heart rate and blood pressure measured on days 4, 7
and 14. *P,0.05 ivabradine versus myocarditis;
NP,0.05 carvedilol
versus myocarditis.
doi:10.1371/journal.pone.0039394.g001
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Hemodynamics of Mice
HRs in the ivabradine and carvedilol groups were significantly
decreased compared with the normal and myocarditis groups on
days 4, 7 and 14 (Figure 1A), but there was no significant
difference between the ivabradine and carvedilol group. Systolic
blood pressure (SBP) in the ivabradine group and carvedilol group
and myocarditis group were significantly decreased compared with
the normal group on days 4, 7 and 14 (Figure 1B). Systolic blood
pressure (SBP) of the carvedilol group and the ivabradine group
slightly increased compared to the myocarditis group on days 7
and 14, but this effect did not reach statistical significance, and
SBP of the ivabradine group did not differ compared to the
carvedilol group. No differences in diastolic blood pressure (DBP)
were found among the ivabradine, carvedilol and myocarditis
groups on days 4, 7 and 14 (Figure 1C).
Echocardiographic Findings
EF and FS in the ivabradine, carvedilol and myocarditis groups
were significantly decreased compared with the normal group on
days 4, 7 and 14. No differences in EF and FS were found among
the ivabradine, carvedilol and myocarditis groups on days 4 and 7
(Figure 2A–B). EF and FS of the ivabradine and carvedilol groups
significantly increased compared to the myocarditis group on day
14, but those of the ivabradine group did not differ compared to
the carvedilol group. LVESd in the ivabradine, carvedilol and
myocarditis groups were significantly increased compared with the
normal group. No differences in LVEDd and LVESd were found
among the ivabradine, carvedilol and myocarditis groups on days
4, 7 and 14 (Figure 2C–D).
Survival Rate
The survival rate in CVB3-inoculated mice followed for 14 days
was 50.0% for those treated with saline, 70.8% for those treated
with ivabradine, and 75.0% for those treated with carvedilol
Figure 2. Echocardiographic study on days 4, 7 and 14. EF, left ventricular ejection fraction; FS: fractional shortening; LVEDd, left ventricular
end-diastolic diameter; LVESd, left ventricular end-systolic diameter. *P,0.05 ivabradine versus myocarditis;
NP,0.05 carvedilol versus myocarditis.
doi:10.1371/journal.pone.0039394.g002
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in CVB3 infected mice.
doi:10.1371/journal.pone.0039394.g003
Figure 4.The effects of ivabradine and carvedilol on plasma noradrenaline on days 4, 7 and 14. *P,0.05 versus myocarditis;
mP,0.05
ivabradine versus myocarditis.
doi:10.1371/journal.pone.0039394.g004
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carvedilol group compared to the myocarditis group, but this effect
did not reach statistical significance.
Plasma Noradrenaline Levels
Plasma noradrenaline levels were significantly higher in the
ivabradine, carvedilol and myocarditis groups than in the normal
group on days 4, 7 and 14 (Figure 4). Noradrenaline of the
carvedilol group significantly decreased compared to the myocar-
ditis group on days 4 and 7, but that of the ivabradine group did
not differ compared to the myocarditis group. Plasma noradren-
aline of the ivabradine and carvedilol groups significantly
decreased compared to the myocarditis group on days 14, and
no difference in plasma noradrenaline were found between the
ivabradine and carvedilol groups on day 14 (Figure 4).
HW/BW Ratio
Four, 7 and 14 days after infection, the myocarditis group
showed a reduction in BW and HW and an increase in HW/BW
ratio. The HW/BW ratio was significantly lower in the ivabradine
and carvedilol groups than in the myocarditis groups on days 7
and 14. No differences in HW/BW ratio were found between the
ivabradine group and carvedilol group (Table 2).
Myocardial Histopathology
On days 4, 7 and 14 at sacrifice, severe injuries to myocardium
with cellular infiltration in the myocarditis group were observed.
The severity of cellular infiltration were significantly reduced in
the ivabradine group and carvedilol group compared with the
myocarditis group on days 7 and 14 (Figure 5, Table 3), indicating
a significantly reduced severity of disease. No differences in the
pathologic scores were found between the ivabradine group and
carvedilol group.
Table 2. Effects of ivabradine and carvedilol on HW/BW on
days 4, 7 and 14.
Group n HW/BW (10
23)
4d 7d 14d
Normal 8 4.3560.18 4.4760.09 4.7660.15
Myocarditis 8 4.8260.12* 5.8460.10* 6.5960.21*
Ivabradine 8 4.7760.16* 5.2560.08*
, { 5.5560.112*
, {
Carvedilol 8 4.7260.10 5.0760.09*
, { 5.4360.07*
, {
*P,0.05 versus normal.
{P,0.05 versus myocarditis.
doi:10.1371/journal.pone.0039394.t002
Figure 5. Histopathology in the heart (Hematoxylin Eosin6200). (A) Histopathology in a normal group (grade 0). (B) Representative
histopathology in a myocarditis group. Several large foci of cellular infiltrations (arrow) in the inflammatory region are shown (grade 3). (C)
Representative histopathology in a ivabradine group. Several small foci of cellular infiltrations in the inflammatory region (arrow) are shown (grade 2).
(D) Representative histopathology in a carvedilol group. Several small foci of cellular infiltrations in the inflammatory region (arrow) are shown (grade
2).
doi:10.1371/journal.pone.0039394.g005
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39394Gene Expression of Cytokines in the Heart
On days 4 and 7, the mRNA levels of the MCP-1, IL-6, TNF-
a, ICAM-1 and VCAM-1 in the myocardium of the infected
mice were significantly upregulated compared with the normal
group. On day 4, cardiac TNF-a. levels were significantly
downregulated in the ivabradine group and carvedilol group
compared with the myocarditis group (Figure 6). On day 7, the
mRNA levels of the IL-6 were significantly lesser in the
ivabradine group and carvedilol group compared with the
myocarditis group (P,0.05; Figure 6), and ivabradine adminis-
tration attenuated the increase in MCP-1 significantly (P,0.05)
in the infected mice, but carvedilol had no effect on the MCP-1.
Ivabradine and carvedilol treatment both led to no significant
reduction in ICAM-1 and VCAM-1 compared to the untreated
infected mice on day 7 (Figure 7). On day 14, no differences in
the mRNA levels of the MCP-1, IL-6, TNF-a., ICAM-1 and
VCAM-1 were found among the ivabradine group and carvedilol
group and myocarditis group.
ELISA Analysis of Cytokines Levels in the Heart
On day 4, there were no significant differences in the cytokine
levels among the ivabradine group and carvedilol group and
myocarditis group. On day 7, the levels of TNF-a and IL-6 were
significantly lower in the ivabradine group and carvedilol group
compared with the myocarditis group (P,0.05; Figure 8), and the
levels of MCP-1 were significantly reduced by ivabradine (P,0.05;
Figure 8), but carvedilol had no effect on the MCP-1. On day 14,
no differences in the levels of the MCP-1, IL-6 and TNF-a. were
found among the ivabradine group and carvedilol group and
myocarditis group.
Viral Genome in the Myocardium
CVB3-RNA abundance by semiquantitative RT-PCR-analysis
were found in the myocardium of the infected mice on days 4, 7
and14. Ivabradine treatment and carvedilol treatment both
produced a slightly higher CVB3-RNA abundance in the infected
myocardium compared to the myocarditis group on days 4
(1.2860.09, 1.2360.07 vs 1.1960.06; Figure 9) and 7 (0.8860.16,
0.8660.06 vs 0.7460.04; Figure 9). There were no significant
differences in the CVB3-RNA abundance among the ivabradine
group and carvedilol group and myocarditis group on day 14.
MDA Contents in the Myocardium
The myocardial MDA contents in the myocarditis group were
significantly higher than those in normal control group (Figure 10).
On days 4, 7 and 14, there were no differences in the myocardial
MDA contents between the myocarditis group and the ivabradine
group. On days 7 and 14, carvedilol manifestedly decreased the
contents of MDA.
SOD Contents in the Myocardium
On days 4, 7 and 14, no differences in the myocardial SOD
contents were found between the ivabradine and myocarditis
groups (Figure 10). On day 14, the contents of SOD were
significantly higher in the carvedilol group than in the myocarditis
groups.
Cardiomyocyte Apoptosis
The TUNEL positive cells in the myocardium of the infected
mice were significantly increased compared with the normal mice.
Carvedilol treatment attenuated the increase in percentages of
apoptosis significantly (P,0.05) in the infected mice, whereas
ivabradine only slightly reduced the percentages of apoptosis in the
infected mice compared with the myocarditis group (Figure 11).
The TUNEL positive cell nuclei appeared condensed and
rounded, showing typical features of apoptotic morphology
(Figure 12).
Discussion
The novel finding of the study is the marked amelioration of
acute viral myocarditis after selective HR reduction with the I(f)
channel inhibitor ivabradine in a CVB3 murine myocarditis
model. Ivabradine and carvedilol treatment result in almost
identical effects. To the best of our knowledge, this is the first study
to investigate the effects of ivabradine in acute viral myocarditis. In
this study, ivabradine, a pure HR-lowering agent, and carvedilol, a
b-blocker, similarly effectively reduced HR, attenuated myocardial
lesions and improved the impairment of left ventricular function.
In addition, ivabradine treatment as well as carvedilol treatment
showed significant effects on altered myocardial cytokines, with a
decrease in the amount of plasma noradrenaline. The increased
myocardial MCP-1, IL-6, and TNF-a. in the infected mice were
significantly attenuated in the ivabradine treatment group.
Ivabradine had no significant anti-oxidative and anti-apoptotic
effects in CVB3-infected mice. These results show that the
protective effects of HR reduction with ivabradine and carvedilol
observed in the acute phase of CVB3 murine myocarditis may be
due not only to the HR reduction itself but also to the
downregulation of inflammatory cytokines. The findings also
show ivabradine to be non-inferior to carvedilol in the setting of
myocarditis.
Table 3. Effects of ivabradine and carvedilol on myocardial histopathology on days 4, 7 and 14.
Group n Infiltration Necrosis
4d 7d 14d 4d 7d 14d
Normal 8 ND ND ND ND ND ND
Myocarditis 8 1.3860.18 2.6360.26 1.8860.13 1.0060.19 1.8860.13 2.3860.18
Ivabradine 8 1.2560.16 1.8760.23
* 1.1360.13
* 0.8860.13 1.360.18
* 1.6360.18
*
Carvedilol 8 1.1360.13 1.6360.26
* 1.060.00
* 0.7560.16 1.160.13
* 1.2560.16
*
ND, not detected.
*P,0.05 versus myocarditis.
doi:10.1371/journal.pone.0039394.t003
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Oxidative Stress
Several reports have suggested that ivabradine may have an
beneficial effect on cardiovascular inflammation [19,21]. Recently,
Custodis et al. demonstrated that ivabradine decreased inflamma-
tory cytokines in apolipoprotein E deficient mice [19]. Schirmer
et al. reported that ivabradine modulated inflammatory cytokine
gene expression and increased endothelial nitricoxide synthase
(eNOS) activity in a murine model of hypercholesterolemic
atherosclerosis [21]. In support of these findings, treatment with
ivabradine in CVB3-infected mice caused a significant improve-
ment in left ventricular function, combined with marked changes
in cytokines expression especially MCP-1, IL-6 and TNF-a.
suppression. It has been suggested that cytokines exert an
important role in the pathophysiology of viral myocarditis [23–
27]. MCP-1 is critically linked to various inflammatory diseases
[28]. MCP-1 stimulates an inflammatory response in cardiomy-
ocytes by enhancing IL-6 levels and is involved in the pathogenesis
of myocarditis [25,29]. IL-6 and TNF-a are both involved in the
pathogenesis of myocarditis and may induce advanced cardiac
dysfunction [24,26,27]. In this study, ivabradine attenuated
myocardial inflammatory lesions and downregulated the levels of
MCP-1, IL-6 and TNF-a. The results suggest that ivabradine
exerts its therapeutic effects in part by suppressing the production
of MCP-1, IL-6 and TNF-a. The decrease in inflammatory
Figure 6. Expression of cytokine mRNAs (A: MCP-1; B: IL-6; C:
TNF-a) in the myocardial tissues of mice on days 4, 7 and 14.
*P,0.05 versus myocarditis;
mP,0.05 versus carvedilol.
doi:10.1371/journal.pone.0039394.g006
Figure 7. Expression of cytokine mRNAs (A: ICAM-1; B: VCAM-
1) in the myocardial tissues of mice on days 4, 7 and 14.
*P,0.05 versus normal.
doi:10.1371/journal.pone.0039394.g007
Ivabradine and Myocarditis
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several mechanisms. First, the effect of ivabradine on myocardial
inflammation is mainly attributed to the reduction in HR.
Increased HR is known to be associated with systemic inflamma-
tion [30]. A reduction in HR will prolong diastolic filling time, and
thus may improve ventricular filling and myocardial O2 supply,
and decrease O2 consumption in impaired left ventricular function
[12]. By preventing myocardial hypoxia, ivabradine may diminish
the production of cytokines such as IL-6 and TNF-a in congestive
Figure 8. Cytokine levels measured by ELISA analysis (A: MCP-
1; B: IL-6; C: TNF-a) in the myocardial tissues of mice on days 4,
7 and 14. *P,0.05 ivabradine versus myocarditis;NP,0.05 carvedilol
versus myocarditis;
mP,0.05 ivabradine versus carvedilol.
doi:10.1371/journal.pone.0039394.g008
Figure 9. CVB-3 RNA abundance in the infected myocardium of
mice on days 4, 7 and 14. nd, not detected.
doi:10.1371/journal.pone.0039394.g009
Figure 10. The effects of ivabradine and carvedilol on MDA and
SOD on days 4, 7 and 14. *P,0.05 carvedilol versus myocarditis.
doi:10.1371/journal.pone.0039394.g010
Ivabradine and Myocarditis
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ventricular filling by the reduction in HR may inhibit the
sympathetic activity. In this study, the plasma noradrenaline levels
in the ivabradine-treatment group were lower than the untreated
infected group on day 14. These data are in agreement with a
earlier study demonstrating that ivabradine significantly reduced
noradrenaline levels in rats with left ventricular dysfunction [12].
In recent years, it has become clear that catecholamines influence
the production of cytokines [32–35]. Therefore, ivabradine may
limit the effect of noradrenaline to prevent the catecholamine-
induced production of cytokines in acute viral myocarditis.
Previous observations have identified anti-oxidative effects as
the underlying mechanisms of the beneficial effect of ivabradine in
atherosclerosis [19,36]. Selective HR reduction with ivabradine
was associated with decreases in NADPH oxidase activity,
superoxide production and lipid peroxidation in the vascular wall
in a previous study conducted in ApoE2/2 mice fed with a
cholesterol-rich diet for 6 weeks [19]. Drouin et al. found that
ivabradine limited cardiac dysfunction and prevented the reno-
vascular and cerebrovascular endothelial dysfunction in dyslipi-
daemic mice, which was associated with the antioxidant effects of
ivabradine [22]. Kro ¨ller-Scho ¨n et al. also showed that ivabradine
improved vascular endothelial function, which was associated with
decreased vascular reactive oxygen species production due to
reduced NADPH oxidase activity and the prevention of eNOS
uncoupling [36]. However, several studies found that ivabradine
had no beneficial effect on oxidative stress [20,21,36]. Kro ¨ller-
Scho ¨n et al. reported that ivabradine had no effect on endothelial
function and vascular reactive oxygen species production in
angiotensin II-treated rats [36]. In a hypercholesterolemic rabbit
model, ivabradine did not attenuate circulating levels of lipid
peroxidation [20]. Similarly, concentrations of reactive oxygen
species were unchanged with ivabradine treatment in a murine
model of hypercholesterolemic atherosclerosis [21]. In the present
study, ivabradine had no significant anti-oxidative effects on the
CVB3-infected myocardium. The discrepancy between the
ivabradine effects on oxidative stress might relate to the different
pathophysiological mechanisms in these different models, the
determined tissue (vessel, circulating plasm, or myocardium), the
treatment duration, or animal species.
Comparison of the Effects of Ivabradine versus Carvedilol
In the present study, both ivabradine and carvedilol similarly
and significantly reduced HR, increased LVEF and improved left
ventricular systolic function. However, mechanisms behind this
protection were different. Recently, we and other investigators
demonstrated that carvedilol, but not metoprolol (a selective b1-
adrenoceptor antagonist), reduced the severity of acute viral
myocarditis in mice, which might be due to its immunoregulatory
and antioxidant effects [7–10]. The antioxidant activity of
carvedilol has been attributed to the carbazole moiety of the drug
[37]. In agreement with the previous studies, we found that
carvedilol exerted some of its beneficial effects by downregulating
the production of IL-6 and TNF-a in the present study. Moreover,
carvedilol, but not ivabradine, had significant anti-oxidative effects
in CVB3-infected mice in the present study. The beneficial action
of carvedilol in murine viral myocarditis may be mainly due to its
blocked b-adrenergic-stimulating effects of catecholamines and
antioxidant properties, and partly due to its HR-lowering effect
[7–10]. Although ivabradine probably mimics in part the effect of
b-blockers in the study, the key mechanism by which ivabradine
exerts these effects is the reduction in HR per se. The reduction in
HR with ivabradine may prolong diastolic filling time, improve the
O2 supply/demand ratio and thus improve ventricular filling and
stroke volume. Moreover, ivabradine lowers HR without any
negative inotropic or lusitropic effect, thus preserving ventricular
contractility. Therefore, the decrease in inflammatory lesions and
the improvement in cardiac function with ivabradine treatment is
probably due not only to the HR reduction itself but also to the
downregulation of inflammatory cytokines. The CVB3 RNA
abundance was performed using semiquantitative RT-PCR. The
CVB3 RNA abundance in the ivabradine and carvedilol groups
was both slightly higher than the untreated infected mice in the
present study. The degree of myocardial inflammation seems to be
more important than CVB3 RNA abundance for the depression of
left ventricular dysfunction in the murine model with the CVB3-
induced viral myocarditis [38]. In addition, it has been suggested
that cardiomyocyte apoptosis may be involved in the course of
experimental viral myocarditis [39,40]. In agreement with
previous studies [39,40], we found that the percentages of
apoptosis in the myocardium of the infected mice were higher
than in the uninfected mice. The interesting finding was that
treatment with carvedilol significantly reduced the apoptosis in the
myocardium of the infected mice, and ivabradine had no
significant anti-apoptotic effects. This indicates that a pure HR
reduction does not account for the effects of b-blockade in
experimental viral myocarditis.
Cardiac vascularization is of importance in the model of
myocarditis. The cardiac vascularization can be stimulated by
long-term HR reduction [41,42]. Several previous studies have
shown that ivabradine have beneficial effects on the capillarization
of heart in experimental models of post-myocardial infarction
heart failure and hypercholesterolemic atherosclerosis [21,43].
Therefore, the improvement of cardiac vasculature may represent
a therapeutic advantage in myocarditis as well. Additional studies
to determine the effects of ivabradine on the cardiac capillarization
in experimental viral myocarditis are needed.
Ivabradine and Large Clinical Trials
A number of experimental studies have demonstrated that
ivabradine have an beneficial effect on left ventricular remodeling
in the failing heart [12–14]. In recent large clinical trials,
ivabradine improved survival in patients with ischemic and
nonischemic causes of heart failure [15,16]. SHIFT trial was
designed to evaluate the effect of HR reduction with ivabradine on
Figure 11. The percentages of apoptosis in the uninfected and
infected myocardium of mice on days 7 and 14. *P,0.05
carvedilol versus myocarditis.
doi:10.1371/journal.pone.0039394.g011
Ivabradine and Myocarditis
PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e39394Figure 12. Detection of apoptotic cardiomyocytes with the TUNEL assay. Apoptosis cell was indicated by a small white arrow. (A) normal
group. (B) myocarditis group. (C) ivabradine group. (D) carvedilol group.
doi:10.1371/journal.pone.0039394.g012
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with symptomatic heart failure and LVEF#35% including
ischemic and nonischemic causes. The primary composite
endpoint of cardiovascular death or hospital admission for
worsening heart failure was significantly reduced, largely due to
a highly significant reduction in hospitalization from heart failure.
The study confirmed HR as an important target in heart failure,
and showed that selective reduction of HR with ivabradine can
improve outcomes [16]. In our study, ivabradine and carvedilol
similarly effectively attenuated myocardial lesions and improved
the impairment of left ventricular function caused by viral
myocarditis.The results of our experiment may not be directly
relevant to the outcomes of clinical trials. To date there is no
clinical trial that is conducted with ivabradine therapy for patients
with viral myocarditis. Therefore, further experimental and
clinical studies would be welcome in future.
In conclusion, these findings indicate that both ivabradine and
carvedilol have a therapeutic benefit in murine CVB3-induced
myocarditis. The cardioprotection of ivabradine and carvedilol
may be due not only to the HR reduction itself but also to the
downregulation of inflammatory cytokines.
Author Contributions
Conceived and designed the experiments: LYC LJF. Performed the
experiments: LYC ZT ZND LQ GLS GXQ. Analyzed the data: LYC ZT
ZND. Wrote the paper: LYC.
References
1. Feldman AM, McNamara D (2000) Myocarditis. N Engl J Med 343: 1388–
1398.
2. Pauschinger M, Doerner A, Kuehl U, Schwimmbeck PL, Poller W, et al. (1999)
Enteroviral RNA replication in the myocardium of patients with left ventricular
dysfunction and clinically suspected myocarditis. Circulation 99: 889–895.
3. Opasich C, Rapezzi C, Lucci D, Gorini M, Pozzar F, et al. (2001) Italian
Network on Congestive Heart Failure (IN-CHF) investigators. Precipitating
factors and decision-making processes of short-term worsening heart failure
despite ‘‘optimal’’ treatment (from the IN-CHF Registry). Am J Cardiol 88: 382–
7.
4. Metra M, Torp-Pedersen C, Swedberg K, Cleland JG, Di Lenarda A, et al.
(2005) Influence of heart rate, blood pressure, and beta-blocker dose on outcome
and the differences in outcome between carvedilol and metoprolol tartrate in
patients with chronic heart failure: results from the COMET trial. Eur Heart J
26: 2259–68.
5. Heusch G (2008) Heart rate in the pathophysiology of coronary blood flow and
myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol
153: 1589–1610.
6. Custodis F, Schirmer SH, Baumhakel M, Heusch G, Bohm M, et al. (2010)
Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol
56: 1973–83.
7. Yue-chun L, Li-sha G, Jiang-hua R, Peng-Lin Y, Jia-Feng L,et al. (2008)
Protective effects of carvedilol in murine model with the coxsackievirus B3-
induced viral myocarditis. J Cardiovasc Pharmacol 51: 92–98.
8. Yue-chun L, Li-sha G, Peng-Lin Y, Ji-Fei T, Jia-Feng L, et al. (2010) Carvedilol
decreases elevated oxidative stress in murine coxsackievirus-induced acute viral
myocarditis. Eur J Pharmacol 640: 112–116.
9. Yue-chun L, Li-sha G, Xue-qiang G, Jia-Feng L (2012) The mechanism of
carvedilol in experimental viral myocarditis. Curr Pharm Des 18: 1620–1624.
10. Nishio R, Shioi T, Sasayama S, Matsumori A (2003) Carvedilol increases the
production of interleukin-12 and interferon-gamma and improves the survival of
mice infected with the encephalomyocarditis virus. J Am Coll Cardilol 41: 340–
345.
11. Bois P, Bescond J, Renaudon B, Lenfant J (1996) Mode of action of bradycardic
agent, S16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol
118: 1051–7.
12. Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, et al. (2004) Long-
term heart rate reduction induced by the selective If current inhibitor ivabradine
improves left ventricular function and intrinsic myocardial structure in
congestive heart failure. Circulation 109: 1674–9.
13. Couvreur N, Tissier R, Pons S, Chetboul V, Gouni V, et al. (2010) Chronic
heart rate reduction with ivabradine improves systolic function of the reperfused
heart through a dual mechanism involving a direct mechanical effect and a long-
term increase in FKBP12/12.6 expression. Eur Heart J 31: 1529–37.
14. Ceconi C, Comini L, Suffredini S, Stillitano F, Bouly M, et al. (2011) Heart rate
reduction with ivabradine prevents the global phenotype of left ventricular
remodeling. Am J Physiol Heart Circ Physiol 300: H366–H373.
15. Swedberg K, Komajda M, Bo ¨hm M, Borer JS, Ford I, et al. (2010) Ivabradine
and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled
study. Lancet 376: 875–85.
16. Tardif JC, O’Meara E, Komajda M, Bo ¨hm M, Borer JS, et al. (2011) Effects of
selective heart rate reduction with ivabradine on left ventricular remodelling and
function: results from the SHIFT echocardiography substudy. Eur Heart J 32:
2507–15.
17. Heusch G (2008) Pleiotropic action(s) of the bradycardic agent ivabradine:
cardiovascular protection beyond heart rate reduction. Br J Pharmacol 155:
970–1.
18. Heusch G, Skyschally A, Gres P, van Caster P, Schilawa D, et al. (2008)
Improvement of regional myocardial blood flow and function and reduction of
infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J
29: 2265–75.
19. Custodis F, Baumhakel M, Schlimmer N, List F, Gensch C, et al. (2008) Heart
rate reduction by ivabradine reduces oxidative stress, improves endothelial
function, and prevents atherosclerosis in apolipoprotein E-deficient mice.
Circulation 117: 2377–87.
20. Busseuil D, Shi Y, Mecteau M, Brand G, Gillis MA, et al. (2010) Heart rate
reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis.
Cardiology 117: 234–42.
21. Schirmer SH, Degen A, Baumha ¨kel M, Custodis F, Schuh L, et al. (2011) Heart-
rate reduction by If-channel inhibition with ivabradine restores collatera lartery
growth in hypercholesterolemic atherosclerosis. Eur Heart J doi: 10.1093/
eurheartj/ehr255. [Epub ahead of print]
22. Drouin A, Gendron ME, Thorin E, Gillis MA, Mahlberg-Gaudin F, et al. (2008)
Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in
dyslipidaemic mice. Br J Pharmacol 154: 749–757.
23. Shioi T, Matsumori A, Sasayama S (1996) Persistent expression of cytokine in
the chronic stage of viral myocarditis in mice. Circulation 94: 2930–7.
24. Seko Y, Takahashi N, Yagita H, Okumura K, Yazaki Y (1997) Expression of
c y t o k i n em R N A si nm u r i n eh e a r t sw i t ha c u t em y o c a r d i t i sc a u s e db y
coxsackievirus B3. J Pathol 183: 105–8.
25. Kolattukudy PE, Quach T, Bergese S, Breckenridge S, Hensley J, et al. (1998)
Myocarditis induced by targeted expression of the MCP-1gene in murine
cardiac muscle. Am J Pathol 152: 101–11.
26. Tanaka T, Kanda T, McManus BM, Kanai H, Akiyama H, et al. (2001)
Overexpression of interleukin-6 aggravates viral myocarditis: impaired increase
in tumor necrosis factor-a. J Mol Cell Cardiol 33: 1627–35.
27. Satoh M, Nakamura M, Satoh H, Saitoh H, Segawa I, et al. (2000) Expression of
tumor necrosis factor-alpha–converting enzyme and tumor necrosis factor-alpha
in human myocarditis. J Am Coll Cardiol 36: 1288–94.
28. Dawson J, Miltz W, Mir AK, Wiessner C (2003) Targeting monocyte
chemoattractant protein-1 signalling in disease. Expert Opin Ther Targets 7:
35–48.
29. Kaya Z, Leib C, Werfel S, Go ¨ser S, O ¨ ttl R, et al. (2011) Comparison of IL-10
and MCP-1-7ND gene transfer with AAV9 vectors for protection from murine
autoimmune myocarditis. Cardiovasc Res 91: 116–23.
30. Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Abedini S, et al. (2004)
Increased heart rate and reduced heart-rate variability are associated with
subclinical inflammation in middle-aged and elderly subjects with no apparent
heart disease. Eur Heart J 25: 363–370.
31. Kapadia SR. (1999) Cytokines and heart failure. Cardiol Rev 7: 196–206.
32. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, et al. (1984) Plasma
norepinephrine as a guide to prognosis in patients with chronic heart failure.
N Engl J Med 311: 819–23.
33. Harris TJ, Waltman TJ, Carter SM, Maisel AS (1995) Effect of prolonged
catecholamine infusion on immunoregulatory function: Implications in conges-
tive heart failure. J Am Coll Cardiol 26: 102–9.
34. Mu ¨ller-Werdan U, Jacoby J, Loppnow H, Werdan K (1999) Noradrenaline
stimulates cardiomyocytes to produce interleukin-6, indicative of a proinflam-
matory action, which is suppressed by carvedilol. Eur Heart J 20(Suppl): P1721.
35. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF (1996)
Epinephrine inhibits tumor necrosis factor-a and potentiates interleukin-10
production during human endotoxemia. J Clin Invest 97: 713–9.
36. Kro ¨ller-Scho ¨n S, Schulz E, Wenzel P, Kleschyov AL, Hortmann M, et al. (2011)
Differential effects of heart rate reduction with ivabradine in two models of
endothelial dysfunction andoxidative stress. Basic Res Cardiol 106: 1147–1158.
37. Feuerstein GZ, Shusterman NH, Ruffolo RR (1997) Carvedilol update IV:
Prevention of oxidative stress, cardiac remodeling and progression congestive
heart failure. Drugs Today 33: 453–473.
38. Pauschinger M, Rutschow S, Chandrasekharan K, Westermann D, Weitz A, et
al. (2005) Carvedilol improves left ventricular function in murine coxsackievirus-
induced acute myocarditis association with reduced myocardial interleukin-
1beta and MMP-8 expression and a modulated immune response. Eur J Heart
Fail 7: 444–452.
Ivabradine and Myocarditis
PLoS ONE | www.plosone.org 12 June 2012 | Volume 7 | Issue 6 | e3939439. Saraste A, Arola A, Vuorinen T, Kyto ¨ V, Kallajoki M, et al. (2003)
Cardiomyocyte apoptosis in experimental coxsackievirus B3 myocarditis.
Cardiovasc Pathol 12: 255–262.
40. Colston JT, Chandrasekar B, Freeman GL (1998) Expression of apoptosis-
related proteins in experimental coxsackievirus myocarditis. Cardiovasc Res 38:
158–168.
41. Zheng W, Brown MD, Brock TA, Bjercke RJ, Tomanek RJ (1999) Bradycardia-
induced coronary angiogenesisis dependent on vascular endothelial growth
factor. Circ Res 85: 192–198.
42. Wright AJ, Hudlicka O (1981) Capillary growth and changes in heart
performance induced by chronic bradycardial pacing in the rabbit. Circ Res
49: 469–478.
43. Ulu N, Henning RH, Goris M, Schoemaker RG, van Gilst WH (2009) Effects of
ivabradine and metoprolol on cardiac angiogenesis and endothelial dysfunction
in rats with heart failure. J Cardiovasc Pharmacol 53: 9–17.
Ivabradine and Myocarditis
PLoS ONE | www.plosone.org 13 June 2012 | Volume 7 | Issue 6 | e39394